TY - JOUR T1 - Granulomatous–lymphocytic interstitial lung disease: an international research prioritisation JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00467-2021 VL - 7 IS - 4 SP - 00467-2021 AU - John R. Hurst AU - S. Hamza Abbas AU - Heba M. Bintalib AU - Tiago M. Alfaro AU - Ulrich Baumann AU - Siobhan O. Burns AU - Alison Condliffe AU - Jesper R. Davidsen AU - Børre Fevang AU - Andrew R. Gennery AU - Filomeen Haerynck AU - Joseph Jacob AU - Stephen Jolles AU - Olivia Lamers AU - Anne Bergeron AU - Marion Malphettes AU - Véronique Meignin AU - Cinzia Milito AU - Tomas Milota AU - Martine Pergent AU - Antje Prasse AU - Isabella Quinti AU - Elisabetta Renzoni AU - Anna Sediva AU - Daiana Stolz AU - Bas Smits AU - Friedolin Strauss AU - Annick A.J.M. van de Ven AU - Joris van Montfrans AU - Klaus Warnatz Y1 - 2021/10/01 UR - http://openres.ersjournals.com/content/7/4/00467-2021.abstract N2 - Granulomatous–lymphocytic interstitial lung disease (GLILD) has been defined as “a distinct clinico-radio-pathological ILD [interstitial lung disease] occurring in patients with CVID [common variable immunodeficiency disorders], associated with a lymphocytic infiltrate and/or granuloma in the lung, and in whom other conditions have been considered and where possible excluded… usually seen in the context of multisystem granulomatous/inflammatory involvement” [1]. The immune and inflammatory complications of CVID such as GLILD are important and associated with reduced survival [2]. However, as a rare manifestation of a rare disease, the scientific understanding and evidence basis to inform effective diagnosis and management of GLILD [3] are limited. There are challenges with the definition of GLILD presented above and the terminology more widely of ILD in people with CVID, which requires further consensus. In this manuscript, we use the term GLILD to describe the heterogeneous ILD seen as part of multisystem immune dysregulation in a substantial minority of people with CVID. A recent international survey of clinicians found little uniformity in diagnostic and therapeutic interventions, identifying an urgent need for new evidence to support consensus guidance [4]. In 2019, the European Respiratory Society (ERS) established a Clinical Research Collaboration to address GLILD (eGLILDnet) [5]. eGLILDnet aims to promote the exchange of research ideas among clinicians and scientists in order to plan, conduct, evaluate and publish clinical and translational studies. Better evidence to diagnose and manage GLILD requires new multicentre research and to this end, we have conducted and here report the results of an international research prioritisation exercise in GLILD. This was a partnership between multiprofessional clinicians and people living with GLILD.The first ever research prioritisation exercise in GLILD: this survey identified areas of interest in the diagnosis, treatment and management of GLILD, which can be used as a roadmap for future research https://bit.ly/3nVuztiWe thank all those who took part in the survey, and staff at the European Respiratory Society, the European Society for Immunodeficiencies and the International Patient Organisation for Primary Immunodeficiencies for their help and support in disseminating the surveys. ER -